NJ State Employees Deferred Compensation Plan maintained its stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the SEC. The fund owned 115,956 shares of the biopharmaceutical company’s stock at the end of the second quarter. Pfizer comprises approximately 0.9% of NJ State Employees Deferred Compensation Plan’s holdings, making the stock its 15th largest position. NJ State Employees Deferred Compensation Plan’s holdings in Pfizer were worth $4,083,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the stock. Dean Investment Associates LLC increased its stake in Pfizer by 4.1% in the second quarter. Dean Investment Associates LLC now owns 25,104 shares of the biopharmaceutical company’s stock worth $884,000 after buying an additional 989 shares during the period. GHP Investment Advisors Inc. increased its stake in Pfizer by 10.3% in the second quarter. GHP Investment Advisors Inc. now owns 8,613 shares of the biopharmaceutical company’s stock worth $303,000 after buying an additional 803 shares during the period. Sawgrass Asset Management LLC bought a new stake in Pfizer during the second quarter worth about $227,000. DIAM Co. Ltd. increased its stake in Pfizer by 10.9% in the second quarter. DIAM Co. Ltd. now owns 1,652,595 shares of the biopharmaceutical company’s stock worth $57,913,000 after buying an additional 162,280 shares during the period. Finally, Forward Management LLC increased its stake in Pfizer by 2.3% in the second quarter. Forward Management LLC now owns 56,137 shares of the biopharmaceutical company’s stock worth $1,977,000 after buying an additional 1,281 shares during the period. Institutional investors own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.003% on Tuesday, hitting $33.679. 11,566,457 shares of the company traded hands. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The stock has a market capitalization of $204.29 billion, a price-to-earnings ratio of 29.857 and a beta of 0.86. The firm’s 50 day moving average price is $34.44 and its 200-day moving average price is $34.14.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The company earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.56 EPS. On average, equities research analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 3.56%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is 95.24%.
A number of analysts recently issued reports on the stock. Argus restated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a report on Sunday, August 28th. Sanford C. Bernstein restated an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Jefferies Group restated a “buy” rating and set a $42.00 price objective (up previously from $41.00) on shares of Pfizer in a report on Tuesday, June 14th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price objective for the company. in a report on Tuesday, June 28th. Finally, Citigroup Inc. restated a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, August 3rd. Ten investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Pfizer currently has a consensus rating of “Buy” and an average target price of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.